[December 20, 2012]

The Rosen Law Firm Announces Investigation of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI

The Rosen Law Firm announces that it is investigating potential securities claims against Pluristem Therapeutics, Inc. (NASDAQ: PSTI) resulting from allegations that the Company may have issued materially inaccurate statements to the investing public.

On May 9, 2012, Pluristem issued an announcement touting that its PLX Cells saved the life of a seven-year old girl. This announcement caused the Company's stock to rise more than 13%. On September 19, 2012 the Company closed a public offering of 8 million shares of common stock - raising over $32 million. In connection with the offering, the Company issued a Prospectus that was filed with the SEC (News - Alert) on September 14, 2012. The Prospectus mentioned the medical results for the seven-year old girl as animportant clinical result supporting the effectiveness of PLX cells, omitting that she later died.

On November 8, 2012, Bloomberg (News - Alert) published an article stating that on or before September 12, 2012 the seven-year old girl had died. This announcement caused the Company's stock to fall, over 22%.

The Rosen Law Firm is investigating a securities class action lawsuit on behalf of Pluristem investors. If you purchased Pluristem securities in the public offering from Jefferies, Oppenheimer & Co., Needham & Co., or Maxim Group LLC, you may be able to recover your investment losses. Please visit the website at http://www.rosenlegal.com to join the prospective action. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

[ Back To Technology News's Homepage ]